INT99965

Context Info Confidence 0.40 First Reported 2001 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 6 Total Number 6 Disease Relevance 4.50 Pain Relevance 0.04

Anatomy Link Frequency outflow 4 NARFL (Homo sapiens)

Pain Link Frequency Relevance Heat Inflammation 16 79.76 metalloproteinase 16 37.28 headache 2 19.80 Angina 3 18.76 anesthesia 7 10.00 lidocaine 10 5.00 agonist 6 5.00 cva 5 5.00 antagonist 3 5.00 tolerance 3 5.00

Disease Link Frequency Relevance Heat Ocular Hypertension 374 100.00 Glaucoma 133 99.40 Hypotension 18 99.40 Macular Edema 24 80.68 Ocular & Orbital Inflammation 2 79.76 Ocular Toxicity (including Many Sub-types) 15 76.96 Postoperative Complications 9 75.00 Increased Venous Pressure Under Development 17 71.28 Cataract 48 59.36 Scotoma 2 48.56

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Supine 2 IOP (31 +/- 2 mmHg) decreased in comparison with prone 2 IOP (P < 0.05) but was relatively elevated in comparison with supine 1 and baseline (P < 0.05).

Positive_regulation (elevated) of Negative_regulation (decreased) of IOP

1) Confidence 0.40 Published 2001 Journal Anesthesiology Section Body Doc Link 11748391 Disease Relevance 0.05 Pain Relevance 0

Therefore, careful monitoring of IOP and IOP-lowering therapy may be necessary, especially in patients with glaucoma who have a compromised outflow facility.

Positive_regulation (necessary) of Negative_regulation (monitoring) of IOP in outflow associated with glaucoma and ocular hypertension

2) Confidence 0.17 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698691 Disease Relevance 1.09 Pain Relevance 0

Therefore, careful monitoring of IOP and IOP-lowering therapy may be necessary, especially in patients with glaucoma who have a compromised outflow facility.

Positive_regulation (necessary) of Negative_regulation (monitoring) of IOP-lowering in outflow associated with glaucoma and ocular hypertension

3) Confidence 0.17 Published 2008 Journal Clinical ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2698691 Disease Relevance 1.09 Pain Relevance 0

Rates of non-compliance with glaucoma treatment instructions are as high as 50%.285 Persistency or maintenance of therapy, involves patient satisfaction with medication tolerability, physician satisfaction with IOP control, medication costs, ease of administration and patient understanding of long term medication use especially where an immediate effect is not noticed.212,286 The need for multiple medications with increasingly complex dosing regimens are real obstacles to good IOP control,285,287 and clearly once daily dosing of PGA is preferred.190

Positive_regulation (obstacles) of Negative_regulation (dosing) of IOP associated with glaucoma and ocular hypertension

4) Confidence 0.04 Published 2010 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2915861 Disease Relevance 0.87 Pain Relevance 0.04

Moreover, the described method was found to result in a satisfactory IOP reduction in refractory glaucoma at 1 year postoperatively with a qualified success rate of 84.2%, comparable to those reported previously.

Positive_regulation (result) of Negative_regulation (reduction) of IOP associated with glaucoma and ocular hypertension

5) Confidence 0.03 Published 2009 Journal Korean Journal of Ophthalmology : KJO Section Body Doc Link PMC2694298 Disease Relevance 0.31 Pain Relevance 0

In 24-hour IOP measurements, latanoprost administered once a day in the evening induces a constant IOP reduction, although the hypotensive effect seems to be greatest during the day (Quaranta et al 2006).

Positive_regulation (induces) of Negative_regulation (reduction) of IOP associated with hypotension and ocular hypertension

6) Confidence 0.02 Published 2008 Journal Clinical Ophthalmology (Auckland, N.Z.) Section Body Doc Link PMC2699817 Disease Relevance 1.08 Pain Relevance 0

General Comments

This test has worked.